nevirapine has been researched along with delavirdine in 127 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 29 (22.83) | 18.2507 |
2000's | 51 (40.16) | 29.6817 |
2010's | 46 (36.22) | 24.3611 |
2020's | 1 (0.79) | 2.80 |
Authors | Studies |
---|---|
Althaus, IW; Biles, C; Busso, M; Genin, MJ; Morge, RA; Resnick, L; Reusser, F; Romero, DL; Tarpley, WG; Thomas, RC | 1 |
Adams, WJ; Biles, C; Evans, DB; Friis, JM; Hosley, JD; Keiser, BJ; Kopta, LA; Morge, RA; Morris, J; Olmsted, RA; Poel, TJ; Romero, DL; Sharma, SK; Stefanski, KJ; Stehle, RG; Tarpley, WG; Thomas, RC; Voorman, RL; Wishka, DG; Yagi, Y | 1 |
Barringer, KJ; Brickwood, JR; Cywin, CL; David, E; Erickson, DA; Grob, PM; Hattox, SE; Hoermann, M; Joseph, DP; Klunder, JM; Pauletti, D; Schwartz, R; Shih, CK; Sorge, CL | 1 |
Mao, C; Sudbeck, EA; Uckun, FM; Venkatachalam, TK | 2 |
Maher, D; Mao, C; Pendergrass, S; Tuel-Ahlgren, L; Uckun, FM; Venkatachalam, TK; Zhu, D | 2 |
Bäckbro, K; Engelhardt, P; Fridborg, K; Högberg, M; Johansson, NG; Kangasmetsä, J; Lövgren, S; Noréen, R; Oberg, B; Sahlberg, BL; Sahlberg, C; Unge, T; Vrang, L; Zhang, H | 1 |
Artico, M; De Montis, F; La Colla, P; Marceddu, T; Massa, S; Silvestri, R | 1 |
Anderson, PS; Bacheler, LT; Corbett, JW; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Garber, S; Gearhart, LA; Jeffrey, S; Klabe, RM; Ko, SS; Logue, K; Magnus, NA; Rodgers, JD; Trainor, GL | 1 |
Andries, K; Arnold, E; Azijn, H; Daeyaert, FF; Das, K; de Béthune, MP; De Corte, BL; de Jonge, MR; Heeres, J; Ho, CY; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Van Aken, KJ; Ye, H | 1 |
Andries, K; Benjahad, A; Grierson, DS; Guillemont, J; Nguyen, CH | 1 |
Andrews, CW; Boone, LR; Chan, JH; Cowan, JR; Creech, KL; Ferris, RG; Freeman, GA; Gonzales, SS; Hazen, RJ; Koszalka, GW; Lowell, GS; Reynolds, DJ; Roberts, GB; Romines, KR; Schaller, LT; Short, SA; St Clair, M; Tidwell, JH; Weaver, K | 1 |
Andries, K; Arnold, E; Boyer, PL; Clark, AD; Clark, P; Daeyaert, F; Das, K; De Béthune, MP; De Corte, B; De Jonge, MR; Heeres, J; Ho, CY; Hughes, SH; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Vinkers, HM; Ye, H | 1 |
Andrews Iii, CW; Boone, LR; Chan, JH; Cowan, JR; Creech, KL; Ferris, RG; Freeman, GA; Gonzales, SS; Hazen, RJ; Hopkins, AL; Koszalka, GW; Lowell, GS; Milton, J; Ren, J; Reynolds, DJ; Roberts, GB; Schaller, LT; Short, SA; Stammers, DK; Stuart, DI; Weaver, K | 1 |
De Corte, BL | 1 |
Andries, K; Arnold, E; Bettens, E; Daeyaert, FF; Das, K; de Béthune, MP; de Jonge, MR; Gaurrand, S; Guillemont, J; Heeres, J; Hertogs, K; Janssen, PA; Koymans, LM; Lewi, PJ; Palandjian, P; Pasquier, E; Pauwels, R; Timmerman, P; Vernier, D; Vinkers, MH; Wigerinck, P | 1 |
Kang, X; Kollman, PA; Kuntz, ID; Wang, J | 1 |
Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
Bettens, E; Demestre, C; Guillemont, J; Heeres, J; Hertogs, K; Lewi, P; Masungi, C; Mordant, C; Pasquier, E; Peeters, A; Queguiner, L; Schmitt, B; Smeulders, L | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
Andrews, CW; Boone, L; Chamberlain, PP; Chan, JH; Ferris, RG; Freeman, A; Hazen, R; Ren, J; Romines, KR; Short, SA; Stammers, DK; Stamp, A; Weaver, KL | 1 |
Cao, Y; De Clercq, E; Liu, X; Pannecouque, C; Wang, Y; Zhan, P | 1 |
Armanasco, N; Azijn, H; de Bethune, MP; Fletcher, P; Harman, S; Manlow, P; Nuttall, J; Perumal, D; Romano, J; Shattock, R | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
De Clercq, E; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P | 1 |
Clercq, ED; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P; Zhu, J | 1 |
Fransen, S; Gupta, S; Huang, W; Paxinos, EE; Petropoulos, CJ; Stawiski, E | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; Liang, YH; Pannecouque, C; Zeng, ZS | 1 |
Balzarini, J; Chen, FE; Clercq, ED; Feng, XQ; He, QQ; Liang, YH; Liu, ZQ; Pannecouque, C; Zeng, ZS | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; He, QQ; Liang, YH; Pannecouque, C; Zeng, ZS | 1 |
Corbau, R; Fishburn, L; Irving, S; Knöchel, T; Martin, A; Mori, J; Mowbray, C; Panton, W; Perros, M; Phillips, C; Ringrose, H; Smith-Burchnell, C; Thornberry, A; Westby, M; Wood, A | 1 |
Haefeli, WE; Weiss, J; Zembruski, NC | 1 |
De Clercq, E; Ge, W; Jiang, Y; Li, Z; Liu, X; Pannecouque, C; Wu, J; Zhan, P; Zhang, J | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Balzarini, J; Chen, FE; Clercq, ED; Dai, HF; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Li, ZM; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P | 1 |
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Briñón, MC; Daelemans, D; Dehaen, W; Leen, V; Madrid, M; Pannecouque, C; Ribone, SR | 1 |
Balzarini, J; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Zhan, P | 1 |
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S | 1 |
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T | 1 |
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z | 1 |
De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Wang, J; Zhan, P | 1 |
De Clercq, E; Du, D; Liu, H; Liu, X; Pannecouque, C; Rai, D; Tian, Y; Wang, L; Zhan, P | 1 |
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Huang, XY; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH | 1 |
Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A | 1 |
Chen, W; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Tian, Y; Wang, L; Zhan, P | 1 |
Balzarini, J; Chen, W; De Clercq, E; Li, X; Liu, H; Liu, X; Lu, X; Pannecouque, C; Zhan, P | 1 |
Ariën, KK; Augustyns, K; Cos, P; Dirié, B; Heeres, J; Joossens, J; Lewi, PJ; Lyssens, S; Maes, L; Michiels, J; Van der Veken, P; Vanham, G; Venkatraj, M | 1 |
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
Chen, FE; Daelemans, D; De Clercq, E; Lu, YP; Mao, TQ; Pannecouque, C; Tao, Y; Wan, ZY; Wang, HF; Wang, XL; Wu, Y; Yao, J; Yin, H | 1 |
Chen, FE; Daelemans, D; De Clercq, E; Mao, TQ; Pannecouque, C; Piao, HR; Tao, Y; Wan, ZY; Wang, YF; Yin, H | 1 |
De Clercq, E; Li, W; Li, X; Liu, X; Zhan, P | 1 |
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Lu, X; Pannecouque, C; Yang, J; Zhan, P; Zhao, F; Zhou, Z | 1 |
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z | 1 |
Gu, SX; Ju, XL; Li, TT; Lu, HH; Pannecouque, C; Xiao, T; Xue, P; Zhang, X; Zheng, XJ; Zhu, YY | 1 |
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Bender, R; Kirsch, R; Kleim, JP; Meichsner, C; Paessens, A; Riess, G | 1 |
Evans, DB; Fan, N; Rank, KB; Sharma, SK; Tarpley, WG; Thomas, RC | 1 |
Chen, IS; Dueweke, TJ; Poppe, SM; Pushkarskaya, T; Stevenson, M; Swaney, SM; Tarpley, WG; Zhao, JQ | 1 |
Arts, EJ; Gu, Z; Li, Z; Quan, Y; Wainberg, MA | 1 |
Gu, Z; Li, X; Parniak, MA; Quan, Y; Wainberg, MA | 1 |
Boucher, CA; Miller, V; Phair, JP; Staszewski, S | 1 |
Coleman, RL; Holtzer, CD | 1 |
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I | 1 |
De Clercq, E | 1 |
Saag, MS; Schooley, RT | 1 |
Ekstrand, DH; Gronowitz, JS; Källander, CF; Rytting, AS; Shao, X; Vrang, L | 1 |
Roca, B; Simón, E | 1 |
Crowe, S | 1 |
Temesgen, Z; Wright, AJ | 1 |
Clotet, B | 1 |
Arnó, A; Blazquez, J; Bloor, S; Bonjoch, A; Casado, JL; Clotet, B; Dronda, F; Garcia-Arata, I; Hertogs, K; Larder, B; Ruiz, L; Van Cauwenberge, A | 1 |
Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
Conway, B | 1 |
Daily, JP; Duan, SX; Giancarlo, GM; Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL | 1 |
Deeks, SG | 1 |
Bacheler, L; Baker, D; Buckery, R; Cordova, B; D'Aquila, R; Gallagher, K; Hanna, G; Hertogs, K; Jeffrey, S; Larder, B; Logue, K; Rizzo, C; Scarnati, H; Tritch, R; Wallace, L | 1 |
Bowers, M | 1 |
Bartlett, JG | 1 |
Cadman, J | 1 |
Adachi, A; Fujiwara, T; Hayami, M; Isaka, Y; Kawauchi, S; Miki, S; Miura, T; Sato, A; Sugimoto, H; Suyama, A; Yoshie, O | 1 |
Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
DiCenzo, R; Morse, GD; Smith, PF | 1 |
Campiani, G; Catalanotti, B; Fattorusso, C; Maga, G; Morelli, E; Nacci, V; Novellino, E; Ramunno, A | 1 |
Kashuba, AD; Rezk, NL; Tidwell, RR | 1 |
Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL | 1 |
Antela, A; Casado, JL; Dronda, F; Gutiérrez, C; Moreno, A; Moreno, S; Pérez-Elías, MJ | 1 |
Dieterich, DT; Kontorinis, N | 1 |
Moyle, GJ | 1 |
de la Rosa, R; Heath, KV; Hogg, RS; Lee, N; Montaner, JS; O'Shaughnessy, MV; Wood, E; Yip, B | 1 |
Hamatake, R; Hong, Z; Zhang, Z | 1 |
Xie, L; Zhou, T | 1 |
Boeri, E; Castagna, A; Gallotta, G; Gianotti, N; Maillard, M; Ratti, D; Serra, G; Tremolada, Y; Vacchini, D | 1 |
Eshleman, SH; Galovich, J; Jackson, JB; Jones, D; Parkin, N; Paxinos, EE; Petropoulos, CJ | 1 |
Bosch, RJ; Clark, SA; Mellors, JW; Shulman, NS | 1 |
Danielson, UH; Geitmann, M; Unge, T | 1 |
Gangakhedkar, RR; Hayatnagarkar, SS; Kurle, SN; Paranjape, RS; Sen, S; Tripathy, SP | 1 |
Anderson, KS; Radzio, J; Sluis-Cremer, N; Xia, Q | 1 |
Barnard, RJ; Felock, P; Hazuda, DJ; Lai, MT; Lu, M; Miller, MD; Munshi, V | 1 |
Cheng, J; Han, N; Liu, YN; Liu, ZY; Wei, HS; Zhang, FJ; Zhao, HX; Zhao, Y | 1 |
Ambrose, Z; Herman, BD; Moore, KL; Nissley, DV; Sheen, CW; Sluis-Cremer, N; Tachedjian, G; Zelina, S | 1 |
Cao, YL; Chen, H; Guo, Y; Li, SX | 1 |
Ariën, KK; Heyndrickx, L; Michiels, J; Quiñones-Mateu, ME; Selhorst, P; Terrazas-Aranda, K; Vanham, G; Vazquez, AC; Vereecken, K; Weber, J | 1 |
Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
Balakrishnan, P; Iqbal, HS; Kumarasamy, N; Saravanan, S; Solomon, S; Solomon, SS; Vidya, M | 1 |
Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT | 1 |
Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
17 review(s) available for nevirapine and delavirdine
Article | Year |
---|---|
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Benzodiazepines; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; Imidazoles; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2005 |
Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
Topics: Acetanilides; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Hydrogen Bonding; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; Nucleosides; Reverse Transcriptase Inhibitors | 1997 |
Use of nonnucleoside reverse-transcriptase inhibitors.
Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Virus Replication | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Efavirenz: resistance and cross-resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; Treatment Failure; Virus Replication | 1999 |
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Phylogeny; Point Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; Virus Replication | 2001 |
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Intestinal Absorption; Male; Nevirapine; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors | 2001 |
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzodiazepinones; Benzoxazines; Cyclopropanes; Delavirdine; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Nevirapine; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine; Uridine | 2002 |
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Delavirdine; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Protease inhibitor-sparing regimens: new evidence strengthens position.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as Topic; Cohort Studies; Cyclopropanes; Delavirdine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunosuppression Therapy; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2003 |
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2004 |
[Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coumarins; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Conformation; Molecular Structure; Nevirapine; Oxazines; Pyranocoumarins; Reverse Transcriptase Inhibitors | 2004 |
110 other study(ies) available for nevirapine and delavirdine
Article | Year |
---|---|
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
Topics: Antiviral Agents; Delavirdine; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 1993 |
Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Biological Availability; Cell Line; Delavirdine; Drug Resistance, Microbial; Drug Stability; HIV Reverse Transcriptase; HIV-1; Indoles; Molecular Structure; Piperazines; Piperidines; Pyridines; Rats; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 1996 |
Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
Topics: Animals; Antiviral Agents; Azepines; Biological Availability; Cell Line, Transformed; Cell Survival; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Stability; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Male; Microsomes, Liver; Mutation; Nevirapine; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 1998 |
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
Topics: Anti-HIV Agents; Delavirdine; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Models, Molecular; Nevirapine; Pyridines; Thiourea | 1999 |
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
Topics: Aminopyridines; Anti-HIV Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Thiourea | 1999 |
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Resistance, Microbial; HIV-1; Injections, Intravenous; Male; Models, Molecular; Molecular Conformation; Rats; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Urea | 1999 |
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
Topics: Anti-HIV Agents; Cells, Cultured; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Pyridines; Reverse Transcriptase Inhibitors; Thiourea; Virus Replication | 1999 |
1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.
Topics: Anti-HIV Agents; Cell Line; Nitroimidazoles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2000 |
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Proteins; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Mutation; Oxazines; Protein Binding; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2000 |
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cell Culture Techniques; Drug Resistance, Multiple; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Models, Molecular; Pyridines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiourea | 2000 |
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
Topics: Anti-HIV Agents; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Mutation; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2001 |
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: HIV-1; Models, Molecular; Molecular Conformation; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2003 |
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Topics: Anti-HIV Agents; Benzophenones; Cell Line; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2004 |
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
Topics: Anti-HIV Agents; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; Models, Molecular; Mutation; Nitriles; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2004 |
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cell Line; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Mutation; Oxazines; Quinolones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2004 |
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2005 |
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
Topics: Allosteric Site; Anti-HIV Agents; Crystallography, X-Ray; Databases, Factual; Drug Design; HIV Reverse Transcriptase; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Statistics as Topic; Thermodynamics | 2005 |
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Female; HIV-1; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Nitriles; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine; Spectrophotometry, Ultraviolet | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Alkynes; Amino Acid Substitution; Benzophenones; Benzoxazines; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; Models, Molecular; Nevirapine; Nitriles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides | 2008 |
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Chemical; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiadiazoles; Virus Replication | 2008 |
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Luciferases; Macrophages; Organ Culture Techniques; Pyrimidines; Reverse Transcriptase Inhibitors; T-Lymphocytes | 2009 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship | 2009 |
Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Binding Sites; Computer Simulation; HIV Reverse Transcriptase; Humans; Imidazoles; Structure-Activity Relationship | 2009 |
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV-1; HIV-2; Humans; Indicators and Reagents; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2010 |
Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cell Line; Computer Simulation; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Naphthols; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nitriles; Protein Binding; Pyridazines; Pyrimidines; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2010 |
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Topics: Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitriles; Pyrazoles; Reverse Transcriptase Inhibitors | 2010 |
Interaction potential of etravirine with drug transporters assessed in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Dogs; Humans; Neoplasm Proteins; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2011 |
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line, Tumor; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Virus Replication | 2011 |
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
Topics: Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
Topics: HIV Reverse Transcriptase; HIV-1; HIV-2; Models, Molecular; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism | 2012 |
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication | 2012 |
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines | 2012 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Antineoplastic Agents; Benzene Derivatives; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship | 2014 |
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
Topics: Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pyridines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Virus Replication | 2014 |
Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Pyrazoles; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Binding Sites; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication | 2014 |
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
Topics: Drug Design; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Mutation; Nitrogen; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Virus Replication | 2014 |
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cells, Cultured; Drug Discovery; HIV Reverse Transcriptase; Humans; Molecular Structure; Nitriles; Piperidines; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; Drug Discovery; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles | 2015 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2016 |
Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
Topics: Acetanilides; Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Models, Molecular; Proton Magnetic Resonance Spectroscopy; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2016 |
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes | 2016 |
Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
Topics: Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Pyrimidines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization | 2017 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Delavirdine; DNA Mutational Analysis; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Imidazoles; Indoles; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Piperazines; Pyridines; Pyridones; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Structure-Activity Relationship | 1994 |
Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
Topics: Amino Acid Sequence; Antiviral Agents; Benzodiazepines; Benzoxazoles; Cloning, Molecular; Delavirdine; HIV Reverse Transcriptase; HIV-1; HIV-2; Imidazoles; Indoles; Kinetics; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Piperazines; Point Mutation; Pyridines; Pyridones; Recombinant Fusion Proteins; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tyrosine | 1995 |
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Topics: Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Cloning, Molecular; Delavirdine; Drug Resistance; HIV Reverse Transcriptase; Imidazoles; Indoles; Molecular Sequence Data; Mutation; Nevirapine; Oligodeoxyribonucleotides; Piperazines; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 1993 |
Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
Topics: Cell-Free System; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; Drug Antagonism; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine | 1995 |
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; DNA; HIV Antibodies; HIV Reverse Transcriptase; Humans; Indoles; Mice; Neutralization Tests; Nevirapine; Peptide Chain Elongation, Translational; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine | 1996 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Topics: Amino Acid Sequence; Anti-HIV Agents; Benzodiazepines; Colorimetry; Delavirdine; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Sequence Data; Nevirapine; Pyridines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Templates, Genetic; Thiourea | 1998 |
[Non-nucleoside reverse transcriptase inhibitors of the human immunodeficiency virus].
Topics: Anti-HIV Agents; Delavirdine; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, University; Humans; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load | 2000 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2000 |
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delavirdine; Humans; Hydrolysis; Inhibitory Concentration 50; Isoenzymes; Microsomes, Liver; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triazolam | 2001 |
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure | 2001 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors | 1996 |
Nevirapine and delavirdine plus protease inhibitors.
Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors | 1996 |
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
NNRTIs: a neglected class.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Strategy update: protease-sparing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides | 1998 |
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; HeLa Cells; HIV Reverse Transcriptase; HIV-2; Humans; Leucine; Molecular Sequence Data; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Simian Immunodeficiency Virus; Species Specificity | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2002 |
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
Topics: Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Caco-2 Cells; Cyclopropanes; Delavirdine; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured | 2002 |
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Delavirdine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oxazines; Prejudice; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delavirdine; DNA, Complementary; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Selection, Genetic; Viremia | 2004 |
Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Clone Cells; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Polymorphism, Genetic; Reverse Transcriptase Inhibitors | 2006 |
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Codon; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV-1; Mutation; Nevirapine; Oxazines; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Virus Replication | 2006 |
Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors.
Topics: Alkynes; Benzoxazines; Binding Sites; Biosensing Techniques; Cyclopropanes; Delavirdine; Enzyme Activation; HIV Reverse Transcriptase; Kinetics; Molecular Structure; Nevirapine; Oxazines; Protein Conformation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Time Factors; Urea | 2006 |
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Molecular Sequence Data; Mutation; Nevirapine; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2007 |
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Catalysis; Cyclopropanes; Delavirdine; HIV Reverse Transcriptase; Kinetics; Models, Molecular; Nevirapine; Protein Conformation; Reverse Transcriptase Inhibitors; Thymine Nucleotides | 2007 |
Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.
Topics: Alkynes; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Electrochemistry; HIV-1; Humans; Luminescent Measurements; Nevirapine; Organometallic Compounds; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA-Directed DNA Polymerase | 2008 |
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; China; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zidovudine | 2007 |
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Topics: Adenine; Anti-HIV Agents; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lamivudine; Microbial Sensitivity Tests; Mutation, Missense; Nevirapine; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Evaluation, Preclinical; Drug Resistance, Viral; Genetic Vectors; HIV Reverse Transcriptase; HIV-1; Humans; Membrane Glycoproteins; Nevirapine; Plasmids; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Transfection; Viral Envelope Proteins; Virion; Virus Replication; Zidovudine | 2009 |
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
Topics: Alkynes; Anilides; Anti-Infective Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Furans; Genotype; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Thiazoles; Thioamides; Thiourea | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; India; Nevirapine; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tertiary Care Centers | 2011 |
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2013 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |